Login

Journal Front Page

News & Events

  • April 2024 Issue delayed
  • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, Volume 13, Issue 2 (April 2024) Issue) schedule published on 15 April 2024 is delay due to some technical problem. It will published on 22 April 2024. Sorry for inconvenience. For other details You can vist the website http://www.ajper.com
  • Call for article for April 2024 issue
  • Submissions of Review, Research Article, Short Communication and Case study are being accepted for the current and future issues before 15 March, 2024 of this journal by online process or editor@ajper.com, or ajper.editor@gmail.com. Further information can be found at www.ajper.com.
  • January 2024 Issue published
  • Dear Researcher, It Pleased to inform you that, Asian Journal of Pharmaceutical Education and Research, has successfully launch Volume 13, Issue 1 (January 2024) Issue). You can find the article on http://ajper.com/current_issue.php Article also invited for the Next coming Issue from your side. For More details Visit: www.ajper.com
  • Application For Reviewer
  • We are now going to reconstitute our editorial board members of Reviewer. Please send your resume at ajper.editor@gmail.com and be a part of the editorial board member as Reviewer.
  • AJPER Impact facor
  • It is to pleasure that Ajper SJIF imact facor has increse from 5.019 to 7.014. Also global impact factor incresed from 0.654 to 0.765.
  • ICV
  • AJPER Rank with Index Copernicus Value 61.10 due to high reputation at International Level

Abstract

FORMULATION AND CHARACTERIZATION OF FAST DISSOLVING ORAL WAFERS OF RIZATRIPTAN

Deepshikha Prasad*, Eisha Ganju, Bhaskar Kumar Gupta

School of pharmacy and research, Peoples University, Bhopal (M.P.)

ABSTRACT

Migraine is a major global health issue that affects over 10% of the population and is the second leading cause of years lived with disability worldwide. Hours or days can pass between migraine attacks, and they typically happen once a month on average Wafers are practical alternative to oral tablets for patients who have difficulty swallowing tablets or have no liquids available at the onset of an attack. Thus, this study aims at developing Fast Dissolving Oral Wafers of Rizatriptan. Oral wafers were prepared by standard methods. The thickness of formulated Rizatriptan was varied between 75±4 μm to 86±3 μm. The formulated. The wafers showed a weight variation between 98±6mg - 124±3 mg. The pH of the formulated wafers was found to be in the range of 6.2±0.2-6.9±0.1. The moisture content of the formulated wafers was found to be in the range of 1.25±0.25 - 1.85±0.14. Thus, it can be considered that the formulation F7 of the Rizatriptan showed minimum moisture content among all formulations. The percentage drug content was between 96.64±0.32% and 99.45±0.18%. The formulated Rizatriptan wafers showed a disintegration time in the range of 8±2-20±5sec (as shown in Table 8.3). Formulation F7 showed the least disintegration time of 8±2 sec. Thus, from results it can be concluded that the formulated oral wafer of Rizatriptan have all ideal properties & can be used as instant remedy to control headache.

Keywords: Fast Dissolving, orally disintegrating Wafers, Rizatriptan, Migraine.


[Full Text Article]